PXS-4699 / Syntara - LARVOL DELTA

Pharmaxis Awarded $1m Australian Government Funding to Progress Duchenne Muscular Dystrophy Drug into the Clinic (Pharmaxis Press Release) - "Pharmaxis Ltd today announced it has been awarded $1 million funding from the Biomedical Translation Bridge (BTB) program to significantly advance work on the company’s drug discovery for the treatment of the devastating genetic disorder Duchenne Muscular Dystrophy (DMD)...The Australian government matched funding will allow the company to take another one of its pipeline of amine oxidase inhibitors (PXS-4699) through to the commencement of human clinical trials."

Financing • New trial • Duchenne Muscular Dystrophy • Genetic Disorders